Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.
18 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall." is generating significant coverage in the Business category, with 23 articles from 18 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Yahoo Finance, BioSpace, finance.yahoo.com and tradingview.com. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 49d ago.
Quick answers
Why is "Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall." trending?
Because 18 independent news sources published 23 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (26)
- Viking Therapeutics Stock Surges 36% Following Weight Loss Drug Study Results Yahoo Finance · 50d ago
- Why Viking Therapeutics Stock Skyrocketed on Tuesday Currently.com · 50d ago
- Viking shares surge on updated obesity drug data BioPharma Dive · 50d ago
- Lilly Rises Higher as Viking Preserves Up to 90% Monthly Yahoo Finance · 50d ago
- Viking achieves ‘maintenance trifecta’ as GLP-1/GIP dual agonist exceeds expectations BioSpace · 50d ago
- VKTX Stock Jumps 36% As Oppenheimer Hikes Target, Peers Call Data A Win finance.yahoo.com · 50d ago
- VKTX Stock Jumps 36% As Oppenheimer Hikes Target, Peers Call Data A Win tradingview.com · 50d ago
- Lilly Rises Higher as Viking Preserves Up to 90% Monthly GuruFocus · 50d ago
- Viking Therapeutics Soars 36% on Clinical Trial Results: “An Important Step” TIKR.com · 50d ago
- VKTX Stock Soars as Viking Therapeutics Announces Positive GLP-1 Trial Results Barchart.com · 50d ago
- Why is Viking Therapeutics stock surging today? Investing.com · 50d ago
- Viking Therapeutics Stock Surges 26% After Weight-Loss Drug Trial barrons.com · 50d ago
- Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results Yahoo Finance · 50d ago
- Viking Therapeutics Stock Surges 36%+ Intraday. It Could Challenge Lilly and Novo's Obesity Empire Moomoo · 50d ago
- Viking touts once-a-month maintenance data for its weight loss candidate Endpoints News · 50d ago
- Viking shares surge on updated obesity drug data Yahoo Finance · 50d ago
- This GLP-1 drug helped people maintain their weight loss in a clinical trial MarketWatch · 50d ago
- 🔎Under the Radar: Viking Stock Gains on Weight-Loss Study WSJ · 50d ago
- Viking Therapeutics Stock Surges 30% After Weight-Loss Drug Trial Barron's · 50d ago
- Viking Therapeutics’ VK2735 Shows Strong Weight-Loss Retention With Monthly Dosing Yahoo Finance · 50d ago
- Viking Therapeutics stock soars on obesity data (VKTX:NASDAQ) Seeking Alpha · 50d ago
- Viking Soars as Obesity Shot Helps Cut Weight in Small Study Bloomberg.com · 50d ago
- Viking Therapeutics: The Market Might Shrug Off The Maintenance Data (NASDAQ:VKTX) Seeking Alpha · 50d ago
- Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens PR Newswire · 50d ago
- VKTX Stock Spikes 38% Premarket: Viking’s VK2735 Shows Promise For Weight-Loss Maintenance Yahoo Finance · 50d ago
- Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall. Investor's Business Daily · 50d ago
Topics
Related trends
Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials
Eli Lilly's experimental triple-hormone drug retatrutide cut knee osteoarthritis pain and produced average weight loss of roughly 25% in two Phase 3 trials involving more than 1,000 adults with obesity.
Obesity drugs may help protect memory and cognitive abilities - News-Medical
A major review of nearly 200 preclinical studies and major clinical trials finds that GLP-1 obesity drugs may protect the brain, but randomized trials have not shown a clear cognitive benefit.
Breakthrough: FDA Approves First Drug Offering a 'Functional Cure' For Chronic Hepatitis B
The US Food and Drug Administration and Health Canada have approved bepirovirsen, marketed as Hibsago, as the first functional cure for chronic hepatitis B.
Can GLP-1s heal the brain? Obesity drugs get a makeover for addiction and depression
Obesity drugs face a major pivot as clinical trials investigate their potential to treat addiction, depression, and criminal behavior.
Experts Identified The Gravest Health Threats Facing Humanity
Researchers identify seventeen major global health threats, highlighting obesity, nuclear war, and artificial intelligence.
What parents should know about GLP-1s for kids
Recent coverage examines the rising use of GLP-1 medications among children, highlighting strong weight loss alongside nutritional and data gaps.